Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
2023 · New England Journal of Medicine · 469 citations
https://doi.org/10.1056/nejmoa2312054
F
Fredrik Schjesvold
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
289
Papers
7.8K
Citations
31
h-index
75
i10-index
Fredrik Schjesvold is an academic researcher from Oslo University Hospital. The author has contributed to research in topics: Multiple Myeloma Research and Treatments & Protein Degradation and Inhibitors & Peptidase Inhibition and Analysis. The author has an h-index of 31, co-authored 246 publications.
ORCID: 0000-0003-1096-0569Papers by this author
worksTreatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
2021 · The Lancet Oncology · 257 citations
https://doi.org/10.1016/s1470-2045(20)30756-7
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage
2021 · Blood Cancer Journal · 164 citations
https://doi.org/10.1038/s41408-021-00587-0
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network
2023 · The Lancet Oncology · 147 citations
https://doi.org/10.1016/s1470-2045(23)00159-6
EHA–EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma
2025 · Nature Reviews Clinical Oncology · 72 citations
https://doi.org/10.1038/s41571-025-01041-x
International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma
2025 · Leukemia · 38 citations
https://doi.org/10.1038/s41375-024-02482-6
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat